Facebook
Twitter
Telegram
Report an ErrorUltragenyx Pharmaceutical Balance Sheet 2011-2024 | RARE
Annual Balance Sheet Ultragenyx Pharmaceutical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | -161 M | -93.6 M | -24.3 M | -7.43 M | -86.2 M | -10.6 M | ||
Long Term Debt |
30.6 M | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
12.6 M | - | - | - | 7.24 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 416 M | 378 M | 35.9 M | 36.3 M | 6.39 M | 561 K | 505 K | 3.62 M | 788 K | 487 K |
Total Current Liabilities |
280 M | 261 M | 181 M | 190 M | 103 M | 74.7 M | 71 M | 60.3 M | 27.9 M | 12.5 M | - | - | - |
Total Liabilities |
1.22 B | 1.19 B | 600 M | 605 M | 482 M | 111 M | 107 M | 66.7 M | 28.5 M | 13 M | 9.54 M | 3.98 M | 1.49 M |
Deferred Revenue |
- | - | - | 59.2 M | - | - | 5.99 M | - | - | - | - | - | - |
Retained Earnings |
-3.39 B | -2.78 B | -2.07 B | -1.62 B | -1.43 B | -1.03 B | -833 M | -531 M | -285 M | -139 M | -74.8 M | -27.1 M | -8.16 M |
Total Assets |
1.49 B | 1.55 B | 1.52 B | 1.76 B | 1.14 B | 720 M | 491 M | 541 M | 560 M | 198 M | 59.6 M | 88.3 M | 12.1 M |
Cash and Cash Equivalents |
214 M | 133 M | 308 M | 714 M | 434 M | 113 M | 100 M | 161 M | 93.6 M | 24.3 M | 7.43 M | 86.2 M | - |
Book Value |
275 M | 352 M | 923 M | 1.15 B | 654 M | 609 M | 383 M | 474 M | 531 M | 185 M | 50.1 M | 84.3 M | 10.6 M |
Total Shareholders Equity |
275 M | 352 M | 923 M | 1.15 B | 654 M | 609 M | 383 M | 474 M | 531 M | 185 M | -74.8 M | -27 M | - |
All numbers in USD currency
Quarterly Balance Sheet Ultragenyx Pharmaceutical
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | 410 K | - | - | - | 701 K | 36.7 M | 36.3 M | 35 M | 29.8 M | 31.2 M | 29.8 M | 29.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.17 B | 1.22 B | 1.21 B | 1.18 B | 1.16 B | 1.19 B | 1.15 B | 643 M | 588 M | 600 M | 551 M | 540 M | 543 M | 605 M | 602 M | 618 M | 624 M | 482 M | 482 M | 482 M | 482 M | 111 M | 111 M | 111 M | 111 M | 107 M | 107 M | 107 M | 107 M | 66.7 M | 66.7 M | 66.7 M | 66.7 M | 28.5 M | 28.5 M | 28.5 M | 28.5 M | 13 M | 13 M | 13 M | 13 M | 9.54 M | 9.54 M | 9.54 M | 9.54 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 5.87 M | 9.08 M | - | 3.91 M | 25.1 M | 66.6 M | 103 M | 66.6 M | 66.6 M | - | 16 K | 55 K | 69 K | - | - | 1.24 M | - | 5.99 M | 5.99 M | 5.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-3.56 B | -3.39 B | -3.26 B | -3.1 B | -2.94 B | -2.78 B | -2.63 B | -2.38 B | -2.23 B | -2.07 B | -1.95 B | -1.88 B | -1.76 B | -1.62 B | -1.6 B | -1.53 B | -1.55 B | -1.43 B | -1.43 B | -1.43 B | -1.43 B | -1.03 B | -1.03 B | -1.03 B | -1.03 B | -833 M | -833 M | -833 M | -833 M | -531 M | -531 M | -531 M | -531 M | -285 M | -285 M | -285 M | -285 M | -139 M | -139 M | -139 M | -139 M | -74.8 M | -74.8 M | -74.8 M | -74.8 M | - | - | - | - | - | - | - | - |
Total Assets |
1.31 B | 1.49 B | 1.24 B | 1.31 B | 1.38 B | 1.55 B | 1.62 B | 1.32 B | 1.38 B | 1.52 B | 1.48 B | 1.51 B | 1.6 B | 1.76 B | 1.27 B | 1.31 B | 1.23 B | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 720 M | 720 M | 720 M | 720 M | 491 M | 491 M | 491 M | 491 M | 541 M | 541 M | 541 M | 541 M | 560 M | 560 M | 560 M | 560 M | 198 M | 198 M | 198 M | 198 M | 59.6 M | 59.6 M | 59.6 M | 59.6 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | - | - | - | - | 154 M | 308 M | 198 M | 291 M | 384 M | 714 M | 714 M | 714 M | 714 M | 434 M | 434 M | 434 M | 434 M | 113 M | 113 M | 113 M | 113 M | 100 M | 100 M | 100 M | 100 M | 161 M | 161 M | 161 M | 161 M | 93.6 M | 93.6 M | 93.6 M | 93.6 M | 24.3 M | 24.3 M | 24.3 M | 24.3 M | 7.43 M | 7.43 M | 7.43 M | 7.43 M | 86.2 M | - | - | - | 10.6 M | - | - | - |
Book Value |
140 M | 275 M | 31.7 M | 129 M | 220 M | 352 M | 469 M | 678 M | 796 M | 923 M | 934 M | 972 M | 1.05 B | 1.15 B | 666 M | 696 M | 609 M | 654 M | 654 M | 654 M | 654 M | 609 M | 609 M | 609 M | 609 M | 383 M | 383 M | 383 M | 383 M | 474 M | 474 M | 474 M | 474 M | 531 M | 531 M | 531 M | 531 M | 185 M | 185 M | 185 M | 185 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
140 M | 275 M | 31.7 M | 129 M | 220 M | 352 M | 469 M | 678 M | 796 M | 923 M | 934 M | 972 M | 1.05 B | 1.15 B | 666 M | 696 M | 609 M | 654 M | 727 M | 820 M | 887 M | 609 M | 609 M | 609 M | 609 M | 383 M | 383 M | 383 M | 383 M | 474 M | 474 M | 474 M | 474 M | 531 M | 531 M | 531 M | 531 M | 185 M | 185 M | 185 M | 185 M | -74.8 M | -74.8 M | -74.8 M | -74.8 M | -27 M | - | - | - | -7.96 M | - | - | - |
All numbers in USD currency